


ADITEC is coordinated by the
Sclavo Vaccines Association
Via Fiorentina 1, 53100 Siena Italy
www.aditecproject.eu



ADITEC: New technologies for improved vaccines

Immunization, the most cost effective health tool ever invented
Immunization is one of the most important health advances in history. Safe and effective, vaccines are a proven tool for controlling and even eliminating devastating infectious disease. Already millions of lives have been saved by vaccinating against deadly diseases like measles, diphtheria, whooping cough, tetanus, polio, mumps, rubella, chicken pox, influenza, meningococcal disease and hepatitis. But we are not there yet.



Today's challenges in vaccine development

Immunization is one of the most important health advances in history. Safe and effective, it's a proven tool for controlling and even eliminating infectious diseases. Today vaccines prevent 2.5 million deaths per year: every minute five lives are saved by vaccines worldwide. Overall, vaccines have done and continue to do an excellent job in eliminating or reducing the impact of infectious diseases. However, despite the huge progress made in past decades, there is still work to be done: for some important diseases we do not have a vaccine yet, and for others, currently available vaccines are not good enough. Several challenges and unmet needs still remain and require an urgent effort in vaccine research and development: emerging infectious diseases, infectious diseases linked to poverty, bacteria resistant to antibiotics and non-communicable diseases such as cancer. Furthermore, vaccines need to be tailored for diverse age and target groups. Thanks to the new technologies vaccines can do much more for the needs of modern society.

New technologies are opening new doors

New immunization technologies that allow for the development of safe and more effective vaccines are needed; vaccines that can protect the world against some devastating diseases. Progress in science and technology is making it possible to achieve what was previously deemed impossible. Thanks to new technologies, vaccines now have the potential to make an enormous contribution to the health of modern society. However, no single laboratory can do modern vaccine science in isolation. Therefore ADITEC brings together all participating laboratories to jointly explore new possibilities.

42 Leading institutes collaborate

The ADITEC project, funded through the 7th Framework Programme of the European Union with a total of €30 million, brings together 42 European research groups, both public institutions and biomedical companies, from 13 EU countries and USA. This powerful partnership is working to produce the necessary knowledge for developing new and powerful technologies for the next generation of vaccines. The project is coordinated by the Sclavo Vaccines Association a jointly founded European non-profit organization devoted to support vaccine research and development.

A future with better vaccines for everyone

The highly innovative ADITEC project will lead to new and more effective vaccines. We see a future where vaccines are administered in novel manners without needles. The formulations are optimized for different age groups, different genders and for people with chronic diseases. All new insights and technologies are shared with partners around the world so, in the future, we are better able to combat devastating diseases.

ADITEC Impact

ADITEC is making significant advances in the development novel immunisation technologies, adjuvants, vectors and delivery systems, formulations and vaccination methods optimised for different age groups. ADITEC has conducted 12 clinical trials and is contributing to international regulation and standards for these novel technologies. Through the project's continual success and achievement, over 206 scientific publications in international peer-reviewed journals have been produced to date.

More information:

www.aditecproject.eu

Facts about ADITEC

Project title: Advanced Immunization Technologies (ADITEC)

Duration: 1 Oct 2011 – 30 Sept 2017

EC contribution: 29.98 million €

Project Coordinator: Rino Rappuoli, Sclavo Vaccines Association

Scientific Coordinator: Donata Medagliani, University of Siena and Sclavo Vaccines Association

Partners: 42 partners from 13 EU countries and the USA

Industrial Involvement: 11 SMEs and 3 big Pharma Industries

ADITEC research partners: 42 partners from 13 EU countries and USA

- Sclavo Vaccines Association (IT)
- Statens Serum Institut (DK)
- Max Planck Institute for Infection Biology (DE)
- Institute Pasteur (FR)
- University of Oxford (UK)
- University of Siena (IT)
- University of Geneva (CH)
- GlaxoSmithKline Vaccines Srl (IT)
- University of Gothenburg (S)
- Academisch Ziekenhuis Leiden (NL)
- Emory University (USA)
- Tuberculosis Vaccine Initiative (NL)
- Infectious Disease Research Institute (USA)
- University of Utrecht (NL)
- Fondazione Humanitas per la Ricerca (IT)
- Fondazione per l'Istituto di Ricerca in Biomedicina (CH)
- Istituto Superiore di Sanità (IT)
- Kings College London (UK)
- World Health Organization (CH)
- Commissariat al Energie Atomique et Aux Energies Alternatives (FR)
- Centre National de la Recherche Scientifique (FR)
- Erasmus Medical Centre (NL)
- ALTA Srl (IT)
- Medicine in Need (FR)
- DeCode (IS)
- Reithera Srl (IT)
- Sigmoid Pharma Limited (IRL)
- Vaccibody AS (N)
- Duotol AB (S)
- Crossbeta Biosciences BV (NL)
- Microbiotec SRL (IT)
- Bioneedle Technologies Group BV (NL)
- GSK Vaccines Institute for global health Srl (IT)
- Seattle Biomedical Research Institute (USA)
- Imperial College of Science, Technology and Medicine (UK)
- University of Surrey (UK)
- University of Innsbruck (A)
- ABERA Bioscience AB (S)
- VisMederi srl (IT)
- Department of Health – Medicines and Healthcare Regulatory Agency (UK)
- Valneva Austria GmbH (A)
- GlaxoSmithKline Biologicals SA (B)